কানাডা - ইংরেজি - Health Canada

jamp pharma corporation - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

কানাডা - ইংরেজি - Health Canada

generic medical partners inc - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

কানাডা - ইংরেজি - Health Canada

laboratoire riva inc. - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

alcon laboratories, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide 10 mg in 1 ml - azopt® is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. azopt is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conducted in pregnant rats administered 0, 2, 6, or 18 mg/kg/day bri

কানাডা - ইংরেজি - Health Canada

hikma canada limited - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

কানাডা - ইংরেজি - Health Canada

alcon canada inc - dorzolamide (dorzolamide hydrochloride); timolol (timolol maleate) - solution - 2.0%; 0.5% - dorzolamide (dorzolamide hydrochloride) 2.0%; timolol (timolol maleate) 0.5% - beta-adrenergic agents

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

sandoz inc - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conduct

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

bryant ranch prepack - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. pregnancy category c developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 62, and 125 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose) during gestation were proportional to the reduced maternal weight gain, with no statistically significant effects on organ or tissue development. increases in unossified sternebrae, reduced ossification of the skull, and unossified hyoid that occurred at 6 and 18 mg/kg were not statistically significant. no treatment-related malformations were seen. following oral administration of 14 c-brinzolamide to pregnant rats, radioactivity was found to cross the placenta and was present in the fetal tissues and blood. there are no adequate and well-controlled studies in pregnant women. brinzolamide ophthalmic suspension 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a study of brinzolamide in lactating rats, decreases in body weight gain in offspring at an oral dose of 15 mg/kg/day (312 times the recommended human ophthalmic dose) were seen during lactation. no other effects were observed. however, following oral administration of 14 c-brinzolamide to lactating rats, radioactivity was found in milk at concentrations below those in the blood and plasma. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from brinzolamide ophthalmic suspension 1%, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. a three-month controlled clinical study was conducted in which brinzolamide ophthalmic suspension 1% was dosed only twice a day in pediatric patients 4 weeks to 5 years of age. patients were not required to discontinue their iop-lowering medication(s) until initiation of monotherapy with brinzolamide ophthalmic suspension 1%. iop-lowering efficacy was not demonstrated in this study in which the mean decrease in elevated iop was between 0 and 2 mmhg. five out of 32 patients demonstrated an increase in corneal diameter of one millimeter. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

কানাডা - ইংরেজি - Health Canada

jamp pharma corporation - dorzolamide (dorzolamide hydrochloride) - solution - 20mg - dorzolamide (dorzolamide hydrochloride) 20mg - carbonic anhydrase inhibitors

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - azopt is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. azopt is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375 times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conducted in pregnant rats administered 0, 2, 6, or 18 mg/kg/day brinz